Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Antonieta Salud-Salvia"'
Autor:
Serafin Morales Murillo, Ariadna Gasol Cudos, Joel Veas Rodriguez, Carles Canosa Morales, Jordi Melé Olivé, Felip Vilardell Villellas, Douglas Rene Sanchez Guzman, Edelmiro Iglesias Martínez, Antonieta Salud Salvia
Publikováno v:
Breast, Vol 56, Iss , Pp 35-41 (2021)
Neoadjuvant chemotherapy (NAC) is an optimal option in early breast cancer, but in ER-positive/HER2-negative (luminal) is still controversial, although a survival benefit has recently been observed when a histological response by Symmans’ method ty
Externí odkaz:
https://doaj.org/article/658cf1ccd10c415eaf74240a272fb44b
Autor:
Serafin Morales Murillo, Ariadna Gasol Cudos, Joel Veas Rodriguez, Carles Canosa Morales, Jordi Melé Olivé, Felip Vilardell Villellas, Douglas Rene Sanchez Guzman, Edelmiro Iglesias Martínez, Antonieta Salud Salvia
Publikováno v:
Future Science OA, Vol 7, Iss 3 (2021)
Background: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus p
Externí odkaz:
https://doaj.org/article/614fe8c76d374c33a3ebf26bd6c67b95
Autor:
Edelmiro Iglesias Martínez, Jordi Melé Olivé, Serafin Morales Murillo, Douglas Rene Sanchez Guzman, Ariadna Gasol Cudós, Carles Canosa Morales, Antonieta Salud Salvia, Joel Veas Rodriguez, Felip Vilardell Villellas
Publikováno v:
Future Science OA
Background: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3cf727f30062e3afa703a9f1304d4d
https://doi.org/10.2144/fsoa-2020-0146
https://doi.org/10.2144/fsoa-2020-0146
Autor:
Edelmiro Iglesias Martínez, Carles Canosa Morales, Joel Veas Rodriguez, Jordi Melé Olivé, Ariadna Gasol Cudós, Serafin Morales Murillo, Felip Vilardell Villellas, Douglas Rene Sanchez Guzman, Antonieta Salud Salvia
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 56, Iss, Pp 35-41 (2021)
Breast, Vol 56, Iss, Pp 35-41 (2021)
Neoadjuvant chemotherapy (NAC) is an optimal option in early breast cancer, but in ER-positive/HER2-negative (luminal) is still controversial, although a survival benefit has recently been observed when a histological response by Symmans’ method ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b54ad9ef0933336edd4db85a974e3da
https://pubmed.ncbi.nlm.nih.gov/33601299
https://pubmed.ncbi.nlm.nih.gov/33601299
Autor:
Marina Pardina, Jm Porcel, Antonieta Salud Salvia, Eleonor Paola Murata, Silvia Bielsa, Laura Porcel
Publikováno v:
Journal of Clinical Oncology. 39:e17534-e17534
e17534 Background: The presence of pleural effusion in the evolution of patients with ovarian cancer is not uncommon. In one series of 123 patients, malignant pleural effusion at the diagnoses was observed in 29%, and 70% during the course of the dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39bdd358be93716c8bc9ce5c86b9e7e5
https://doi.org/10.1200/jco.2021.39.15_suppl.e17534
https://doi.org/10.1200/jco.2021.39.15_suppl.e17534
Autor:
Jordi Melé Olivé, Antonieta Salud Salvia, Felipe Vilardell Villellas, Ester Morera Morillo, Ariadna Gasol Cud\\'s, Carles Canosa Morales, Douglas Rene Sanchez Guzman, Serafin Morales Murillo
Publikováno v:
Journal of Clinical Oncology. 39:e12609-e12609
e12609 Background: Endocrine sensitivity (ES) determined by response to the Ki67 index to short-term preoperative endocrine therapy (ET) is accepted but not included in adjuvant treatment decision. However, genomic platforms have been incorporated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23841295d473c987a5afff84f7161553
https://doi.org/10.1200/jco.2021.39.15_suppl.e12609
https://doi.org/10.1200/jco.2021.39.15_suppl.e12609
Autor:
Elena Elez, Raquel Comas, Josep Tabernero, Bernardo Queralt, Javier Ros Montañá, Davide Ciardiello, Rodrigo Dienstmann, Ana Vivancos, Rodrigo A. Toledo, Guillem Argiles, Xavier Hernandez Yague, Antonieta Salud Salvia, Nuria Mulet, Jose Luis Cuadra, Hector G. Palmer, Ariadna Garcia, Iosune Baraibar, Giulia Martini, Guillermo Villacampa, Irene Chicote
Publikováno v:
Web of Science
4112 Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- MEK inhibitor, has been shown to improve outcomes. Pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460c4929c7a604858bbd7c7617691d71
https://doi.org/10.1200/jco.2020.38.15_suppl.4112
https://doi.org/10.1200/jco.2020.38.15_suppl.4112
Autor:
Teresa Rodriguez, Antonieta Salud Salvia, Ramon Salazar, Clara Montagut, Josep Tabernero, Ferran Losa, Cristina Gravalos Castro, Carles Pericay, T. García, Begoña Graña Suárez, Rosario Vidal, David Marrupe, Auxiliadora Gómez-España, Enrique Aranda, Maria Jose Safont, Javier Gallego Plazas, Helder Mansinho, Alfredo Carrato, Jose Luis Manzano Mozo, M. Pilar Escudero
Publikováno v:
Journal of Clinical Oncology. 37:TPS3618-TPS3618
TPS3618 Background: Both anti-EGFR and anti-VEGF therapies have shown clinical benefit when they are added in first and second-line in L-sided CRC. The conflicting results in anti-VEGF vs. anti-EGFR studies (FIRE-3, PEAK and CALGB/SWOG 80405 studies)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3a7c23a8f42b75bd2f80061376dad24
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3618
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3618
Autor:
Beatriz García Paredes, Maria Jose Ortiz, I. Alés, Manuel Valladares-Ayerbes, Enrique Aranda, Javier Sastre, Guillermo Alfonso Quintero Aldana, Juan José Reina-Zoilo, Luis Robles, Eduardo Díaz-Rubio, Adelaida La Casta Munoa, Antonieta Salud Salvia, Pilar García-Alfonso, Jose María Vieitez, Javier Gallego Plazas, Maria Jose Safont, Guillot Mónica, Carlos López-López, Eduardo Polo Marques, Rafael López
Publikováno v:
Journal of Clinical Oncology. 37:3549-3549
3549 Background: The outcome for mCRC has changed since the introduction of new chemotherapy schedules and targeted therapies, however new predictive biomarkers are needed. bCTCs and BRAF / PIK3CA mutations have been studied as a potential predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6e91a8c79997fe66c7ad506c85b34bf
https://doi.org/10.1200/jco.2019.37.15_suppl.3549
https://doi.org/10.1200/jco.2019.37.15_suppl.3549
Autor:
Rafael López, Antonieta Salud Salvia, Eduardo Díaz-Rubio, Begoña Graña Suárez, Beatriz García Paredes, Silvia Gil Calle, Rocio Garcia-Carbonero, Carmen Guillen, Maria Jose Safont, Javier Sastre, Guillermo Alfonso Quintero Aldana, Maria Auxilidora Gomez-España, Encarnación González Flores, Eva Martínez de Castro, Mercedes Salgado Fernández, Juan José Reina-Zoilo, Enrique Aranda, Pilar García-Alfonso, Jose María Vieitez, Adelaida La Casta Munoa
Publikováno v:
Journal of Clinical Oncology. 37:3507-3507
3507 Background: FOLFOXIRI+BEV has demonstrated a survival benefit compared with FOLFIRI plus BEV (TRIBE Lancet Oncol 2015) in first-line mCRC. Nevertheless, due to its safety profile, this schedule is not recommended for all pts. In addition, we hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2d02914911952b4ab67d86c7d1f8fb3
https://doi.org/10.1200/jco.2019.37.15_suppl.3507
https://doi.org/10.1200/jco.2019.37.15_suppl.3507